Collectively, these findings advance the pharmacological landscape of GLP-1 and its derived peptides, suggesting that they are versatile agents for comprehensive treatment strategies for chronic pain syndromes linked with metabolic disorders. Here, GLP1R is linked to Other metabolic disease.